Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis (Q36369266)

13 August 2017

1 reference

title

Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis (English)

1 reference

13 August 2017

1 reference

1 reference

1

Fred Saad

1 reference

13 August 2017

James McKiernan

2

1 reference

13 August 2017

James Eastham

series ordinal

3

1 reference

13 August 2017

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

24

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

4-12

1 reference

13 August 2017

cites work

Cancer statistics, 2004

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Radical prostatectomy for clinically localized prostate cancer: long-term results of 1,143 patients from a single institution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Immediate dual energy X‐ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Low bone mineral density in hormone-naïve men with prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Osteoporosis due to cancer treatment: pathogenesis and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Treatments for improving survival of patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Mortality and institutionalization following hip fracture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Osteonecrosis of the jaws associated with cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Bisphosphonates and bone necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Bisphosphanates and Oral Cavity Avascular Bone Necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Costs of prostate cancer, metastatic to the bone, in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Metastatic prostate cancer: complications and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

U.S. Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Management of Bone Loss in Men With Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.06.020

10.1016/J.UROLONC.2005.06.020

7 January 2021

Identifiers

DOI

1 reference

13 August 2017

1 reference